BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 197.5 SEK | +1.96% |
|
+0.41% | -26.25% |
| Apr. 22 | Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest | DJ |
| Apr. 15 | Nordic Shares Moved Upward Monday; Invisio Led Increases | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,357 | 8,401 | 10,497 | 23,972 | 23,651 | 17,444 | - | - |
| Enterprise Value (EV) 1 | 7,271 | 7,422 | 9,664 | 23,176 | 23,044 | 16,606 | 16,270 | 15,289 |
| P/E ratio | 94.9 x | -122 x | -87.6 x | -2,092 x | 103 x | 993 x | 38.5 x | 14.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 29.7 x | 127 x | 454 x | 104 x | 38.4 x | 34.7 x | 17.3 x | 7.81 x |
| EV / Revenue | 25.8 x | 113 x | 418 x | 101 x | 37.4 x | 33 x | 16.1 x | 6.85 x |
| EV / EBITDA | 59.7 x | -100 x | -76.3 x | -8,251 x | 85 x | 3,694 x | 57.5 x | 17.1 x |
| EV / FCF | 22.5 x | -70.8 x | -66.7 x | -522 x | - | 128 x | 33.7 x | 14.3 x |
| FCF Yield | 4.45% | -1.41% | -1.5% | -0.19% | - | 0.78% | 2.97% | 6.99% |
| Price to Book | 8.57 x | 9.26 x | 13.3 x | 30.5 x | 22.6 x | 16.5 x | 11.9 x | 11 x |
| Nbr of stocks (in thousands) | 88,060 | 88,060 | 88,060 | 88,132 | 88,315 | 88,323 | - | - |
| Reference price 2 | 94.90 | 95.40 | 119.2 | 272.0 | 267.8 | 197.5 | 197.5 | 197.5 |
| Announcement Date | 2/6/20 | 2/4/21 | 2/3/22 | 2/3/23 | 2/14/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 281.8 | 65.94 | 23.15 | 229.9 | 616 | 502.5 | 1,010 | 2,233 |
| EBITDA 1 | 121.7 | -74 | -126.6 | -2.809 | 271.1 | 4.496 | 282.8 | 892.5 |
| EBIT 1 | 112.5 | -85.01 | -139.7 | -17.44 | 252.6 | 2.068 | 415.4 | 1,562 |
| Operating Margin | 39.92% | -128.92% | -603.66% | -7.59% | 41.01% | 0.41% | 41.12% | 69.97% |
| Earnings before Tax (EBT) 1 | 113 | -86.69 | -140.5 | -11.17 | 276.5 | 34.5 | 575.7 | 1,579 |
| Net income 1 | 88.5 | -68.52 | -119.8 | -11.18 | 229.2 | 16.9 | 453.6 | 1,240 |
| Net margin | 31.41% | -103.9% | -517.54% | -4.86% | 37.22% | 3.36% | 44.91% | 55.54% |
| EPS 2 | 1.000 | -0.7800 | -1.360 | -0.1300 | 2.590 | 0.1990 | 5.130 | 14.05 |
| Free Cash Flow 1 | 323.9 | -104.9 | -144.8 | -44.4 | - | 130 | 483 | 1,069 |
| FCF margin | 114.94% | -159.02% | -625.78% | -19.32% | - | 25.87% | 47.81% | 47.85% |
| FCF Conversion (EBITDA) | 266.06% | - | - | - | - | 2,891.46% | 170.76% | 119.74% |
| FCF Conversion (Net income) | 365.98% | - | - | - | - | 769.18% | 106.47% | 86.16% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/4/21 | 2/3/22 | 2/3/23 | 2/14/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 2.746 | 208.8 | 11.02 | 18.2 | 311.3 | 52.05 | 65.5 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | -100.9 | 131 | -78.09 | -81.75 | 194.5 | -74.95 | -82 |
| Operating Margin | - | - | -3,673.31% | 62.73% | -708.35% | -449.07% | 62.48% | -143.99% | -125.19% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | -44.26 | 293.9 | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.5000 | 3.310 | -1.160 | 1.410 | -0.9900 | -0.8000 | 2.200 | -0.5000 | -0.5000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/28/22 | 4/27/23 | 7/12/23 | 11/8/23 | 2/14/24 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,086 | 979 | 833 | 795 | 607 | 838 | 1,174 | 2,155 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 324 | -105 | -145 | -44.4 | - | 130 | 483 | 1,069 |
| ROE (net income / shareholders' equity) | 8.9% | -7.28% | -14.1% | -7.1% | 25% | 4.5% | 33.7% | 55.5% |
| ROA (Net income/ Total Assets) | 6.87% | -6.14% | -12.3% | -1.27% | 22.4% | -4.24% | 37.6% | 42.2% |
| Assets 1 | 1,289 | 1,117 | 974 | 878.9 | 1,022 | -398.3 | 1,206 | 2,937 |
| Book Value Per Share 2 | 11.10 | 10.30 | 8.960 | 8.920 | 11.90 | 12.00 | 16.60 | 17.90 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 12.8 | - | 15.5 | 16.5 | 29 |
| Capex / Sales | - | - | - | 5.55% | - | 3.08% | 1.63% | 1.3% |
| Announcement Date | 2/6/20 | 2/4/21 | 2/3/22 | 2/3/23 | 2/14/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
197.5
SEK
Average target price
366.2
SEK
Spread / Average Target
+85.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.25% | 1.59B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BIOA B Stock
- Financials BioArctic AB
